Pressmeddelande -

New research data with C21 on diabetes

- Dr Chow et al, Melbourne: C21 has an anti-aterosclerotic effect in animal models with diabetes.

- Dr Liu et al, Beijing: C21 protects the pancreas against damages caused by high fat intake.

Dr Bryna Chow and co-workers, from the internationally renowned research group at Baker Institute in Melbourne, have studied the effects of C21 on mechanisms involved in the atherosclerotic process in a diabetic animal model. The results were recently published on-line in the journal ‘Diabetologia’ In this study, biomarkers of inflammation and oxidative stress (free radicals) in the vascular wall was analyzed. In addition, the extent of atherosclerotic damage (plaques) to the aorta was measured. Link to abstract
- Dr Chow, Melbourne: “ C21 significantly reduced the extent of atherosclerotic damage to the aortic vascular wall. We analyzed a large number of biomarkers and have shown that C21 reduces inflammation in the vasculature and also reduces the harmful increased oxidative stress, seen in diabetes. These mechanisms, we believe, contribute to the anti-atherosclerotic effect of C21.”

- Prof Terri Allen, project leader at BakerIDI Heart and Diabetes Institute, Melbourne; “By adding an antagonist of the AT2-receptor, in addition to treatment with the AT2-receptor stimulating agent C21, we noted that all protective effects of C21 could be blocked. This series of experiments shows that the protective effects of C21 are mediated via stimulation of the AT2-receptor.C21 may potentially in the future become a new anti-atherosclerotic drug for use in patients with diabetes.”

Min Liu, Beijing: High fat intake may cause reduced insulin sensitivity and impaired glucose tolerance due to harmful effects on the insulin producing islets in pancreas. In a Chinese animal study, presented at the American Diabetes Association meeting in New Orleans in June, Dr Liu et al. have shown that such damage is reduced following 4 weeks treatment with orally administered C21, once daily. These results indicate that C21 has a direct protective effect on insulin producing cells in the body. Such effects may prove therapeutically beneficial for patients whose blood sugar is difficult to control. Link to abstract

For more information, please contact:
Per Jansson, CEO
Tel: +46 (0)709-17 47 46, e-mail:

Vicore Pharma develops small molecule drugs that stimulate the AT2 receptor in the Renin-Angiotensin-System (RAS), an endogenous protection and repair system. Our vision is to establish a new class of effective drugs to treat serious disease where inflammation, fibrosis and impaired neuronal function are significant pathologies. The company’s lead drug candidate C21 is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF), and is currently in clinical Phase I. The parent company to Vicore Pharma, Vicore Pharma Holding is listed on Nasdaq First North, a small cap list on the Stockholm stock exchange. 

For further information, see


Nina Carlén

Presskontakt IR, Communication and Administration Coordinator 0763-909404

Leif Darner

Presskontakt Styrelseordförande 0705-79 04 62

Per Jansson

Presskontakt VD 0709-174746